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Abstract
Genomic instability is a hallmark feature of cancer cells, and can be caused by defective DNA repair, for instance due to
inactivation of BRCA2. Paradoxically, loss of Brca2 in mice results in embryonic lethality, whereas cancer cells can tolerate
BRCA2 loss. This holds true for multiple DNA repair genes, and suggests that cancer cells are molecularly “rewired” to cope
with defective DNA repair and the resulting high levels of genomic instability. In this study, we aim to identify genes that
genomically unstable cancer cells rely on for their survival. Using functional genomic mRNA (FGmRNA) profiling, 16,172
cancer samples were previously ranked based on their degree of genomic instability. We analyzed the top 250 genes that
showed a positive correlation between FGmRNA levels and the degree of genomic instability, in a co-functionality network.
Within this co-functionality network, a strong cluster of 11 cell cycle-related genes was identified, including TPX2. We then
assessed the dependency on these 11 genes in the context of survival of genomically unstable cancer cells, induced by
BRCA2 inactivation. Depletion of TPX2 or its associated kinase Aurora-A preferentially reduced cell viability in a panel of
BRCA2-deficient cancer cells. In line with these findings, BRCA2-depleted and BRCA2-mutant human cell lines, or tumor
cell lines derived from Brca2–/–;p53–/– mice showed increased sensitivity to the Aurora-A kinase inhibitor alisertib, with
delayed mitotic progression and frequent mitotic failure. Our findings reveal that BRCA2-deficient cancer cells show
enhanced sensitivity to inactivation of TPX2 or its partner Aurora-A, which points at an actionable dependency of
genomically unstable cancers.
Introduction
Genomic instability is a common feature of human cancers,
and drives the progressive accumulation of genomic aber-
rations, including somatic copy-number alterations
(SCNAs) and segmental or whole-chromosome aneu-
ploidies [1]. The extent of genomic instability varies across
different tumors, ranging from tumors with relatively few
SCNAs (e.g., acute myeloid leukemia) to tumors that harbor
excessive SCNAs (e.g., high-grade serous ovarian cancer
(HGSOC) and triple-negative breast cancer (TNBC)) [2–4].
Tumors with relatively high levels of genomic instability
typically behave aggressively, with early (visceral) meta-
static spread and have a poor prognosis. Unfortunately,
these tumors lack the “oncogenic drivers” that are currently
actionable, omitting these patients to benefit from the
available molecular targeted agents [5, 6].
Genome maintenance is tightly controlled by checkpoint
mechanisms that coordinate cell cycle progression with
DNA repair, and coordinate faithful chromosome
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segregation during mitosis [7]. Genomic instability can be
caused, among other events, by mutations in DNA repair
genes. For instance, tumors arising in women carrying
germline heterozygous mutations in the homologous
recombination (HR) DNA repair genes BRCA1 or BRCA2
are extensively genomically unstable [8].
During the S/G2-phase of the cell cycle, HR repair is
required to faithfully repair DNA double-stranded breaks
(DSBs) using a sister chromatid as the repair template [9].
Both BRCA1 and BRCA2 act to facilitate the loading of
RAD51 recombinase, which is ultimately responsible for
strand invasion and recombination [10]. When HR is
defective, error-prone DNA repair pathways, including
nonhomologous end joining (NHEJ) and single-strand
annealing (SSA) are utilized, resulting in loss of genomic
integrity [11].
The requirement of HR for cellular viability is illustrated
by the phenotype observed in Brca2 knockout mouse
models, as Brca2-deficient mice die early in embryogenesis,
with elevated levels of DNA damage that lead to cell cycle
arrest [12, 13]. In stark contrast, tumor cells are apparently
able to cope without BRCA2. These observations are not
unique to BRCA2 loss, as cellular viability also reduces
upon loss of the HR repair factor BRCA1 [12, 14]. In part,
survival of HR-defective cancer cells can be explained by
loss of the tumor-suppressor p53. In line with this notion,
BRCA1 and BRCA2-mutant cancer cells almost invariably
have TP53 mutations; however, the combined inactivation
of BRCA2 or BRCA1 and TP53 still yields cells that display
impaired proliferation [12]. Very likely, multiple other
genetic alterations influence the viability of HR-defective
cancer cells.
Unraveling how genomically unstable tumors are mole-
cularly “rewired” to survive high levels of genomic
instability may provide a strategy to target these tumors.
Previous studies have shown that genomically unstable
tumors can show an addiction toward genes that secure their
survival [15, 16]. Targeting these genes could result in the
development of molecular treatment regimens tailored to
patients with genomically unstable cancers.
Previously, we employed functional genomic mRNA
(FGmRNA) profiling to determine the degree of genomic
instability in 16,172 patient-derived tumor samples [2].
Herein, associations between the expression of individual
genes and their association to the degree of genomic
instability were assessed. In the current study, we found
that the top 250 genes positively associated with the
degree of genomic instability, revealed a strong network
of genes with shared functionality implicated in the cell
cycle, including TPX2. The relevance of the genes within
this cluster was tested using in vitro models, in which
genomic instability was induced by BRCA2 inactivation.
Our findings show that BRCA2-deficient cancer cells
show enhanced sensitivity to inactivation of TPX2 or its
partner Aurora-A. These results point at actionable
dependencies of genomically unstable cancers on faithful
mitotic processes.
Results
Identification of a cluster of genes of which
individual gene expression positively associates to
the degree of genomic instability
To identify genes that are potentially involved in the
molecular “rewiring” of tumor cells to cope with high levels
of genomic instability, we built on a previously described
data set, in which a transcriptome-wide association analysis
was performed between the expression of individual genes
and the degree of genomic instability in 16,172 tumor
samples [2] (Fig. 1a). We selected the top 250 genes that
showed the strongest association between elevated mRNA
levels and the degree of genomic instability (Fig. 1b). These
250 genes were analyzed for predicted co-functionality,
which revealed a strong cluster of 11 genes (with a corre-
lation coefficient >0.5), implicated in cell cycle regulation,
including TPX2 (Fig. 1c).
TPX2 depletion preferentially affects viability in
BRCA2-depleted cells
To test the relevance of the identified 11 genes in cellular
survival of genomically unstable cancer cells, we modeled
genomic instability in vitro by doxycycline-inducible
shRNA-mediated depletion of the DNA repair protein
BRCA2. Treatment of BT-549-shBRCA2dox cells with
doxycycline resulted in a robust reduction of BRCA2 pro-
tein (Fig. 2a) and BRCA2 mRNA (Fig. 2b). More impor-
tantly, a functional assay to test the ability to repair through
HR by analysis of irradiation-induced RAD51 foci, showed
that doxycycline-induced depletion of BRCA2 resulted in a
virtual complete loss of RAD51 irradiation-induced foci
(IRIF) formation to DSBs marked by γH2AX foci (42% vs
0.4% of cells with ≥5 RAD51 foci per cell, in control-
depleted vs BRCA2-depleted cells) (Fig. 2c, d).
siRNA was used to deplete each of the selected 11 genes
in BT-549-shBRCA2dox cells. Despite using five indepen-
dent siRNA sequences, we were not able to deplete
WDR67, and for this reason left this gene out for further
analysis. Doxycycline treatment prior to transfection did not
affect siRNA efficiency, as no significant differences in
reduction of mRNA expression of the ten genes in the
presence or absence of doxycycline were observed by qRT-
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PCR (Suppl. Figure 1a), nor did doxycycline treatment
affect cell cycle progression (Suppl. Figure 1b). Cell sur-
vival was assessed at 5 days after siRNA transfection, using
two independent siRNAs per gene, in the absence or pre-
sence of doxycycline (Fig. 2e, Suppl. Figure 1c). BIRC5,
UBE2C, and RAD21 appeared essential in our setup, as
depletion of these genes led to low cell counts, both in
BRCA2-deficient and BRCA2-proficient cells. Depletion of
CDCA3, SKP2, MYBL2, or CENPA did not affect survival
regardless of BRCA2 status (Fig. 2e, Suppl. Figure 1c). In
contrast, TPX2, KIF2C, and DEK were conditionally
required, as depletion of these genes led to significantly
lower numbers of viable cells in BRCA2-deficient cells
compared to BRCA2-proficient cells (Fig. 2e, Suppl. Figure
1c). Depletion of TPX2, a microtubule-associated protein,
led to the largest differential levels of viable cells when
comparing BRCA2-deficient with BRCA2-proficient BT-
549 cells (siTPX2 #1 p= 0.0002; siTPX2, #2 p= 0.0002)
(Fig. 2e, Suppl. Figure 1c).
TPX2/Aurora-A depletion affects viability in BRCA2-
depleted breast cancer cells
To test whether the reduction in cell viability of BRCA2-
deficient cells upon TPX2 depletion was also observed in
other cancer models, we engineered four other breast cancer
cell lines with doxycycline-inducible BRCA2 shRNAs:
SUM149-shBRCA2dox, MDA-MB231-shBRCA2dox, HCC38-
shBRCA2dox, and HCC1806-shBRCA2dox. Treatment with
doxycycline reduced BRCA2 protein levels in all cell lines
(Suppl. Figure 2), and resulted in impaired HR, as illustrated
by the reduced amount of RAD51 IRIF formation (Fig. 3a, b).
A robust reduction in cell viability of BRCA2-deficient cells
compared to BRCA2-proficient cells after TPX2 depletion
was observed in HCC38-shBRCA2dox (siTPX#1, p= 0.01,
siTPX2#2, p= 0.04) and HCC1806-shBRCA2dox (siTPX2#2,
p= 0.003) (Fig. 3c, Suppl. Figure 2b).
TPX2 is a microtubule-associated protein and a cofactor
of Aurora-A kinase. Binding of TPX2 to Aurora-A leads to
activation of and subsequent localization of Aurora-A to
microtubules during mitosis to facilitate bipolar spindle
formation and thus faithful chromosome segregation [17].
We next tested if Aurora-A inactivation using RNAi
resulted in similar effects in BRCA2-depleted cells (Fig. 3c,
Suppl. Figure 2b). Depletion of Aurora-A led to a reduction
in cell survival of BRCA2-deficient cells compared to
BRCA2-proficient cells in BT-549-shBRCA2dox
(siAURKA#2, p= 0.02) and HCC38-shBRCA2dox cells
(siAURKA#1, p= 0.02; siAURKA#2, p= 0.03) (Fig. 3c,
Suppl. Figure 2b).
BRCA2-deficient cells have impaired DNA repair capa-
city, and may rely for their survival on residual DNA repair
pathways, such as non-homologous end joining (NHEJ). To
test if TPX2 depletion impacts on DNA repair capacity, we
analyzed the amounts of DNA lesions in TPX2-depleted
proliferating cells. Numbers of spontaneous 53BP1 foci
were not increased, whereas a minor, but statistically sig-
nificant increase in γ-H2AX foci was observed in EdU-
positive cells (Fig. 3d). In response to IR, TPX2-depleted
cells did not show delayed clearance of γ-H2AX and 53BP1
foci (Fig. 3e, Suppl. Figure 3f), suggesting that the observed
effects of TPX2 depletion in BRCA2-depleted cells are not
caused through interference with residual DNA repair
capacity in BRCA2-depleted cells.
Fig. 1 Identification of a cluster of genes of which individual gene
expression associates to the degree of genomic instability. a Ranked
associations of mRNA expression of individual genes and their asso-
ciation to the degree of genomic instability (z-scores). b, c Co-
functionality analysis based on similar biological processes of the top
250 genes (b), of which expression is positively associated with
genomic instability, revealed a cluster of 11 genes (correlation coef-
ficient > 0.5) (c)
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Upregulation and downregulation of TPX2 levels
affects mitotic fidelity
Since TPX2 depletion preferentially affects cell survival
in BRCA2-depleted cancer cells and because TPX2
functions in mitotic spindle assembly, we examined
whether progression through mitosis is aberrant in
BRCA2-deficient cells. To this end, we stably transduced
BT-549-shBRCA2dox cells with GFP-tagged histone—
H2B and assessed chromosome segregation and duration
of mitosis using time-lapse microscopy (Fig. 4a).
BRCA2-deficient cells displayed more aberrant mitoses
(12.6% vs 2.4% in BRCA2-proficient cells, p= 0.03)
(Fig. 4b). The number of cells undergoing cell death in the
course of the experiment did not differ between BRCA2-
proficient and BRCA2-deficient cells (8.5 vs 6.2% of cells
that underwent mitosis, respectively, p= 0.56) (Fig. 4c).
The mean duration of mitosis amounted to 57 min in
BRCA2-proficient compared to 80 min in BRCA2-
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Fig. 2 TPX2 depletion preferentially affects cell viability in BRCA2-
deficient cancer cells. a BT-549-shBRCA2dox cells were left untreated
or were treated with doxycycline (2 or 4 days), and subsequently
harvested for western blotting for BRCA2 and actin. b BT-549-
shBRCA2dox cells were treated as in panel A, and mRNA expression
levels of BRCA2 were analyzed relative to GAPDH using qRT-PCR. c
BT-549-shBRCA2dox cells were grown on coverslips and treated with
doxycycline (3 days) and/or irradiated (IR, 5 Gy) as indicated. At 3 h
after irradiation, cells were fixed and analyzed for RAD51 and γH2AX
foci formation. Scale bars represent 5 μm. d Percentages of cells with
≥5 RAD51 foci per nucleus are indicated. (n ≥ 50 per condition). e BT-
549-shBRCA2dox cells were treated with doxycycline (3 days) and
were subsequently transfected with indicated siRNAs. A total of
30,000 cells were plated 48 h following transfection. Viable cells were
counted 5 days later. Percentages of cell survival of doxycycline-
treated vs untreated cells are depicted. Error bars indicate standard
deviations of two experimental replicates. Unpaired two-tailed t tests
were used to test for statistical significance (*p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001)
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Fig. 3 Depletion of TPX2 or Aurora-A reduces cell viability of
BRCA2-deficient breast cancer cells. a HCC1806-shBRCA2dox,
HCC38-shBRCA2dox, SUM149-shBRCA2dox, and MB231-
shBRCA2dox were grown on coverslips and treated with doxycycline
(3 days) and/or irradiated (IR, 5 Gy) as indicated. Subsequently, cells
were stained for RAD51 and γH2AX. Scale bars represent 5 μm. b
Quantification of results from a. Percentages of cells with ≥5 RAD51
foci per nucleus are indicated (n ≥ 31). c Percentages of cell survival of
doxycycline-treated cells vs untreated cells, transfected with indicated
siRNAs. Unpaired two-tailed t tests were used to test for statistical
significance (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001). d BT-549 cells were
transfected with siTPX2 or control siRNA (CTR). Cells were grown
on coverslips for 3 days after which they were incubated with EdU
conjugated to azide-Alexa 488 (10 μM) for 15 min. Subsequently, cells
were fixed and stained for 53BP1 and γH2AX. Amounts of 53BP1 and
γH2AX foci per cell of at least 30 EdU-positive cells were counted.
Means and standard deviations are depicted. Mann–Whitney U tests
were used to analyze statistical significance (*p ≤ 0.05, **= p ≤ 0.01,
***p ≤ 0.001, ns not significant). e BT-549 cells were transfected as in
d, irradiated (IR, 5 Gy), and fixated 0.5 or 6 h after irradiation.
Amounts of 53BP1 and γH2AX foci per cell were counted. Means and
standard deviations are depicted. Mann–Whitney U tests were used to
analyze statistical significance (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ns
= not significant)
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Using FGmRNA profiling, we found that elevated
mRNA levels of TPX2 were associated with a high degree
of genomic instability. We argued that TPX2 amplification
alone was likely not sufficient to rescue the loss of viability
induced by BRCA2 inactivation since genomically unstable
tumors typically harbor multiple structural chromosomal
aberrations. Indeed, stably increased TPX2 expression upon
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expression in BT-549-shBRCA2dox cells), did not lead to a
rescue of the loss of viability induced by BRCA2 depletion
(Fig. 4e, f, and Suppl. Figure 3a, b). Also, TPX2 over-
expression did not result in significantly different levels of
Caspase-3 cleavage, a measure of apoptosis (Suppl. Figure
3c), nor was HR function influenced by TPX2 over-
expression, as assessed by RAD51 IRIF formation (Suppl.
Figure 3d, e). Rather, time-lapse microscopy revealed that
overexpression of TPX2 significantly prolonged the dura-
tion of mitosis, and increased cell death and the amount of
aberrant mitoses (Suppl. Figure 4a–d).
In an attempt to explain the reduction in cell survival,
observed preferentially in BRCA2-deficient cells after
TPX2 depletion, we assessed whether BRCA2-deficient
cells might become more dependent on TPX2 for faithful
completion of mitosis. For this purpose, we followed BT-
549-shBRCA2dox cells depleted of TPX2 using time-lapse
microscopy (Fig. 4g). Depletion of TPX2 increased mitotic
duration in both BRCA2-proficient and BRCA2-deficient
cells (p= 0.78) (Fig. 4d, j), and the amount of mitotic
aberrations increased in both BRCA2-proficient and
BRCA2-deficient cells (p= 0.58) (Fig. 4b, h). Most of the
mitotic aberrations involved failure to perform cytokinesis
(data not shown). Depletion of TPX2 resulted in increased
amounts of mitotic cells that eventually died (Fig. 4c). A
robust increase in cell death was observed in BRCA2-
deficient cells depleted of TPX2 compared to untreated
BRCA2-deficient cells (Fig. 4c, i; p < 0.0001). Only a very
subtle increase in cell death was observed in BRCA2-
proficient cells depleted of TPX2 when compared to
untreated BRCA2-proficient cells (Fig. 4c, i; p= 0.58). In
line with the results of cell survival assays (Figs. 2e and 3c),
failed mitoses in cells depleted of both TPX2 and BRCA2
resulted more frequently in cell death, when compared to
BRCA2-proficient cells depleted of TPX2 (p= 0.02) (Fig.
4i).
BRCA2-mutant cancer cells are more sensitive to
Aurora-A inhibition
Since Aurora kinase A, which is associated with TPX2, is
currently tested as a therapeutic target in cancer treatment
[18], we investigated whether BRCA2-mutant cancer cells
were more sensitive to chemical inhibition of Aurora-A. For
this purpose, we tested the effects of the Aurora-A inhibitor
alisertib in mouse mammary tumor cell lines derived from
Tp53–/–;Brca2wt/wt or Tp53–/–;Brca2F11/F11 mice (denoted as
Brca2wt/wt, Brca2F11/F11). As a control, we used Tp53–/–;
Brca2F11/F11 cells, reconstituted with a human BRCA2
cDNA (denoted Brca2F11/F11+ iBac-Brca2). As expected,
RAD51 IRIF formation was impaired in the Brca2F11/F11
mouse mammary tumor cells, but was restored in Brca2F11/
F11
+ iBac-Brca2 (Suppl. Figure 5a, b). Treatment with
alisertib efficiently reduced phosphorylation of histone H3
(pH3) at serine-10, a substrate of Aurora-A, illustrating
efficient target engagement at indicated doses (Fig. 5a).
Simultaneously, alisertib treatment resulted in an accumu-
lation of cells in G2/M-phase of the cell cycle (from 25.0%
in control cells to 60.7% in cells treated with 200 nM ali-
sertib) (Fig. 5a). Treatment with alisertib also increased the
number of cells in mitosis (2.6% in untreated cells to 9.2%
after treatment with 200 nM alisertib), as judged by staining
for MPM2, a mitotic marker (Fig. 5a). Importantly,
Brca2F11/F11 cells were significantly more sensitive to ali-
sertib compared to Brca2wt/wt or Brca2F11/F11+ iBac-Brca2
cells in short-term MTT assays (Fig. 5b) and clonogenic
survival assays (Fig. 5c, d). Importantly, at the doses used,
alisertib preferentially affected Aurora-A kinase activity,
whereas at higher concentrations also the activity of Aurora-
B and Aurora-C was inhibited (Suppl. Figure 6b). Also,
while alisertib treatment preferentially affected BRCA2-
depleted cells, the Aurora-B inhibitor ZM447439 affected
cells regardless of BRCA2 status (Suppl. Figure 6c).
To validate whether reduced cell viability upon TPX2
and Aurora-A depletion is also observed in human BRCA2-
mutant cells, we used human colorectal DLD-1 cells.
BRCA2–/– DLD-1 cells are HR-defective, as assessed by
RAD51 IRIF formation (Suppl. Figure 5c, d). TPX2 and
Aurora-A were successfully depleted in wt DLD-1 cells
Fig. 4 Depletion of TPX2 leads to aberrant mitoses. a BT-549-
shBRCA2dox cells, stably expressing H2B–GFP were treated with
doxycycline (24 h), and subsequently followed with live-cell micro-
scopy for 65 h. The left panel represents untreated cells, the right panel
represents doxycycline-treated cells. Each bar represents a single cell:
green bars indicate normal mitoses, blue bars indicate cells with
aberrant mitoses, and black dots indicate cell death. b Percentages of
BT-549-shBRCA2dox cells, left untreated or treated with doxycycline,
that showed aberrant mitoses (unpaired two-tailed t test, p= 0.03). c
Percentages of BT-549-shBRCA2dox cells, left untreated or treated
with doxycycline, that died (unpaired two-tailed t test, p= 0.56). d
Duration of mitosis in BT-549-shBRCA2dox cells, treated with or
without doxycycline. Means and standard errors of the mean are
depicted (unpaired two-tailed t test, p= 0.12). e BT-549-shBRCA2dox
cells were infected with pBabe-EV or pBabe-TPX2, and immuno-
blotted for TPX2 and actin. f Clonogenic survival assay of BT-549-
shBRCA2dox cells, infected with pBabe-EV or pBabe-TPX2, and
treated with or without doxycycline as indicated. g BT-549-
shBRCA2dox cells were transfected with TPX2 siRNA and treated
with doxycycline or left untreated, and were followed with live-cell
microscopy for 65 h. Each bar represents a single cell: green bars
indicate normal mitoses, blue bars indicate cells with aberrant mitoses,
and black dots indicate cell death. h Percentages of mitotic aberrations
in BT-549-shBRCA2dox cells transfected with TPX2 siRNA and
treated with or without doxycycline (unpaired two-tailed t test, p=
0.58). i Percentages of cell death after mitosis in BT-549-shBRCA2dox
cells, transfected with TPX2 siRNA and treated with or without
doxycycline (unpaired two-tailed t test, p= 0.02). j Duration of
mitosis in BT-549-shBRCA2dox cells transfected with TPX2 siRNA,
and treated with or without doxycycline. Means and standard errors of
the mean are depicted (unpaired two-tailed t test, ns not significant)
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using siRNA (Suppl. Figure 5f), and the number of viable
cells was assessed after 5 days (Fig. 5e and Suppl. Figure
5e). We found that in BRCA2-mutant cells, depletion of
TPX2 and Aurora-A also reduced cell viability in pre-
ferentially BRCA2–/– DLD-1 cells compared to BRCA2 wt
DLD-1 cells (siTPX2#1, p < 0.0001; siTPX2#2, p < 0.0001;
siAURKA#1, p= 0.0034; and siAURKA#2, p= 0.0026,
Fig. 5e). In line with the results of short-term survival
assays, treatment with alisertib resulted in a preferential loss
of viability in BRCA2–/– DLD-1 cells when compared to
BRCA2 wt cells in clonogenic survival assays (Fig. 5f, g).
Altogether, our data indicate that BRCA2 inactivation ren-
ders cancer cells dependent on the TPX2/Aurora-A signal-
ing axis for their survival.
Alisertib treatment impedes cytokinesis which is
preferentially cytotoxic in BRCA2-deficient cells
In order to investigate the cell fate of BRCA2-inactivated
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Fig. 5 BRCA2-mutant cancer
cells are differentially sensitive
to Aurora-A inhibition. a BT-
549 cells were left untreated or
treated with 200 and 1000 nM of
alisertib for 24 h. Cells were
fixed and co-stained for pHH3,
MPM2, and DNA was stained
using propidium iodide. Cells
were analyzed by flow
cytometry. Percentages of cells
stained positive for pHH3 and
MPM2 are quantified. b Mouse
mammary tumor cells were
treated with indicated
concentrations of alisertib.
Results of three replicates were
analyzed using ANOVA with
Bonferroni post test, p < 0.05 at
200 nM. c Mouse mammary
tumor cells were treated
continuously with alisertib, and
clonogenic cell survival was
assessed. d Quantifications of
colony numbers of three
independent experiments as
performed in c. Statistical
analysis was done using
ANOVA with Bonferroni post
test, p < 0.01 at 100 nM. e
Percentages of cell survival of
BRCA2–/– DLD-1 vs wt DLD-1
cells after transfection with
siRNAs (unpaired two-tailed t
test, TPX2: #1 p= 0.0006, #2 p
= 0.0007, AURKA: #1 p=
0.0034, and for #2 p= 0.0026).
f wt and BRCA2–/– DLD-1 cells
were treated with indicated
concentrations of alisertib and
clonogenic survival was
assessed. g Quantifications of
colony numbers of three
independent experiments as
performed in g. Statistical
analysis was done using
ANOVA with Bonferroni post
test, p < 0.001 at 20 nM and, p <
0.01 at 40 nM
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BRCA2 wt DLD-1 cells using live-cell microscopy (Fig.
6a). As expected, alisertib treatment resulted in reduced
phosphorylation of HH3, and an increased number of
mitotic BRCA2 wt DLD-1 cells (Suppl. Figure 6a). Treat-
ment with alisertib increased mitotic duration in BRCA2 wt
cells (p < 0.01) and to a greater extent in BRCA2–/– (p <
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0.001) DLD-1 cells compared to untreated BRCA2 wt and
BRCA2–/– DLD-1 cells (Fig. 6a–c). Also, the amount of
mitotic aberrations increased upon alisertib treatment.
While in alisertib-treated BRCA2 wt DLD-1 cells, 19% of
the mitoses were aberrant, alisertib-treated BRCA2–/– DLD-
1 cells displayed aberrations in 85% of the mitoses (p <
0.001) (Fig. 6d). Aberrant mitoses led to cell death in 48.0%
of BRCA2–/– cells compared to 19.4% in BRCA2 wt DLD-1
cells treated with alisertib (p < 0.001) (Fig. 6e). Of note, the
majority of aberrant mitoses in BRCA2–/– cells treated with
alisertib involved cytokinesis failure (54.5% in BRCA2–/–
compared to 6.4% in wt DLD-1 cells) (Fig. 6f). Notably,
when alisertib was tested on non-transformed MCF10A
cells, we did not observe pronounced cell death, but did
detect nuclear abnormalities (Suppl. Figure 6d, left panels),
and arrested proliferation (Suppl. Figure 6d, right panel).
Collectively, our results suggest that BRCA2-inactivated
cells are more sensitive to inactivation of the TPX2/Aurora-
A kinase signaling axis compared to BRCA2-proficient
cells, which is likely attributed to an increase in mitotic
aberrations.
To further substantiate our findings, we analyzed the
effects of BRCA2 inactivation and alisertib treatment at the
genomic level. To this end, we used single-cell whole-
genome sequencing (Fig. 6g, Suppl. Fig. 7). As expected,
BRCA2 inactivation leads to increased numbers of focal
copy-number alterations (Fig. 6g, left panel), whereas ali-
sertib treatment resulted in whole-chromosome aneuploidies
(Fig. 6g, right panel). Notably, the increased degree of
whole-chromosome aneuploidies was not observed in cells
with combined alisertib treatment and BRCA2 depletion,
which was very likely a consequence of these cells dying.
Remarkably, alisertib treatment also resulted in increased
numbers of focal copy-number alterations (Fig. 6g, left
panel). These aberrancies may reflect DNA damage that
arises as a consequence of aberrant mitoses [19, 20], which
may be specifically toxic in HR-deficient cancer cells.
Discussion
Out of the 11 genes that were identified as part of a co-
functionality cluster, we focused on TPX2. Previously,
TPX2 was shown to be amplified in a number of genomi-
cally unstable cancers, including gastric, colon, oral squa-
mous cell carcinoma, and ovarian cancer [21]. Beyond
TPX2 amplification, elevated protein levels of TPX2 are
frequently reported in cancer [22–24], although these effects
may be indirectly caused by high levels of proliferation,
since TPX2 is post-translationally regulated during the cell
cycle [25]. Regardless of whether TPX2 overexpression is
caused by the underlying amplification, overexpression of
TPX2 positively correlates with tumor grade, stage, lymph
node metastasis, remote metastasis, recurrence, and a poor
prognosis and poor patient survival [22, 23, 26]. These
observations are in line with genomically unstable tumors
that are more often high-grade tumors with a poor prognosis
[2, 27].
Our results indicate that cancer cells, especially those
with defective HR, increasingly depend on the presence of
TPX2, or its associated kinase Aurora-A, for their survival.
AURKA still ranked within the top 15% of genes positively
associated with genomic instability at place 2012. TPX2
ranked clearly higher, which is in line with a previous study,
in which TPX2 but not AURKA was part of the CIN70 set of
genes which is positively associated with chromosomal
instability (CIN) [28]. These differences likely represent
alternative means by which gene activation is achieved in
cancer cells, or differential requirements for TPX2 and
Aurora-A in achieving elevated Aurora-A kinase activity.
In this study, HR inactivation was modeled through
BRCA2 inactivation. In line with this, a single-nucleotide
polymorphism (SNP) near the AURKA gene was previously
associated with cancer risk in BRCA2 mutation carriers
[29]. Yet, in our FGmRNA analysis, genomically unstable
samples were included regardless of the underlying gene
mutations. It is therefore unlikely that sensitivity toward
TPX2 or Aurora-A inactivation is restricted to BRCA2-
defective cells. Very likely, TPX2/AURKA overexpression
or gene amplifications are only allowed in specific genetic
Fig. 6 Depletion of Aurora-A impedes cytokinesis and is preferentially
cytotoxic in BRCA2-deficient cells. a wt and BRCA2–/– DLD-1 cells
stably expressing H2B–GFP were followed with live-cell microscopy
for 65 h. The left panel shows the mitotic behavior of wt DLD-1 cells
and the right panel the mitotic behavior of BRCA2–/– DLD-1 cells.
Each bar represents a single cell: green bars indicate normal mitoses,
blue bars indicate aberrant mitoses, and cell death is indicated with a
black dot. b wt and BRCA2–/– DLD-1 cells stably expressing H2B–
GFP and treated with 200 nM alisertib. Graph depictions are similar as
in a. c Quantification of the duration of mitosis of wt and BRCA2–/–
DLD-1 cells treated with 200 nM alisertib or untreated. The median
with interquartile range is depicted. Significance was tested with a
Kruskal–Wallis test with Dunn’s multiple comparisons, *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001, ns not significant. d Percentages of wt and
BRCA2–/– DLD-1 cells treated with 200 nM alisertib or not, with
mitotic aberrations. e Percentages of wt and BRCA2–/– DLD-1 cells
treated with 200 nM alisertib or left untreated, that undergo cell death
(Kruskal–Wallis test with Dunn’s multiple comparisons, *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001, ns not significant). f Pie charts with the
different types of mitotic aberrations in wt and BRCA2–/– DLD-1 cells
treated with 200 nM alisertib. g BT-549-shBRCA2dox cells were pre-
treated for 3 days with doxycycline and treated with alisertib for an
additional 2 days. Cells were single-cell sorted and whole-genome
sequenced. The number of focal aberrations and the number of whole-
chromosome aberrations per cell were counted. Medians with inter-
quartile range are depicted and statistical analyses were performed
using a Kruskal–Wallis test with Dunn’s multiple comparisons, *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, ns not significant
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contexts. It would be interesting to further investigate which
genetic aberrations co-occur with TPX2/AURKA, to further
guide the clinical implementation of Aurora kinase
inhibitors.
One possible explanation for the observed dependence of
BRCA2-inactivated cells on TPX2 could be that TPX2 is
required for residual DNA repair in HR-deficient cells, for
instance, through non-homologous end joining (NHEJ).
However, we did not observe altered kinetics of DNA
damage clearance of IR-induced DNA damage. These
observations are in good agreement with previously pub-
lished genome-wide shRNA screens for DNA repair reg-
ulators [30, 31]. In these studies, loss of canonical NHEJ
regulators (including PRKDC and XRCC4 and XRCC5)
resulted in compensation through elevated HR, which was
not observed upon TPX2 or Aurora-A depletion (Suppl.
Figure 3g). These data suggest that increased dependence
on TPX2 or Aurora-A is not due to a role for TPX2 or
Aurora-A in DNA repair.
We did observe a small but statistically significant
increase in the amount of DNA breaks in TPX2-depleted
cells (Fig. 3d), and increased numbers of structural genomic
aberrations upon alisertib treatment (Fig. 6g). Inhibition of
Aurora-A was previously shown to cause mitotic aberra-
tions, including delayed mitotic entry, multipolar spindles,
and defective cytokinesis, which leads to ensuing aneu-
ploidy [32, 33]. Importantly, mitotic failure was shown to
cause DNA damage [19, 20]. Such ensuing DNA lesions
after mitotic defects may cause DNA replication defects in
the subsequent round of cell division, and lead to a mitotic
catastrophe in HR-deficient cells [34–36].
Alternatively, the high proliferation rates and fre-
quently compromised DNA repair in genomically
unstable cancer cells, may make these cells increasingly
dependent on mitotic processes in general for faithful cell
division. Notably, also BRCA2 has been implicated in
regulating mitotic progression, specifically in cytokinesis
[37], and BRCA1 has been demonstrated to bind and
control Aurora-A [38]. This may lead to a general
dependence on mitotic regulators. Yet, our original 11-
gene cluster contained multiple mitotic regulators, of
which only two genes (TPX2 and KIF2C) showed dif-
ferential effects in BRCA2-proficient vs BRCA2-deficient
cells. Also, while Aurora-A inhibition preferentially
affected BRCA2-depleted cells, Aurora-B inhibition did
not (Suppl. Figure 6c). Future research is warranted to test
whether other components of the mitotic spindle or
spindle assembly checkpoint are conditionally required in
BRCA2-defective cells. In this context, especially MAD2
and CDC20 are interesting, as their expression is highly
correlated to TPX2 levels [39].
Although no chemical TPX2 inhibitors are currently
available, Aurora-A inhibitors have been extensively stu-
died. Notably, cancers driven by MYC amplification were
shown to be selectively sensitive to Aurora-A inhibition
[32, 40, 41]. Specifically, AURKA and TPX2 together with
MYC appear to act as driver genes in MYC-driven cancers
[40]. Because TP53 loss and MYC amplification is often
observed in genomically unstable cancers [4, 21], Aurora-A
inhibitors may offer therapeutic benefit to patients with
genomically unstable cancers.
The Aurora-A inhibitor alisertib (also known as
MLN8237) has been tested preclinically and clinically,
either alone or in combination therapy [32, 41]. Especially
in combination therapy with spindle poisons such as tax-
anes, alisertib induces antitumor effects, for instance, in
in vivo TNBC models [42]. Our analysis of MCF10A cells
showed that non-transformed cells do display nuclear
abnormalities and arrested proliferation in response to ali-
sertib treatment, which warrants an assessment of long-term
effects on normal tissues. Clinically, antitumor effects of
alisertib were reported in solid and hematological cancers
[43–45], and long-term progression-free survival or com-
plete response was observed in some cases in patients with
solid cancers or in patients with recurrent ovarian cancer
[46, 47].
Notably, inhibition of Aurora-A and CHEK1, a DNA
damage checkpoint kinase, showed synergistic effects
in vitro, which was attributed to a G2/M-phase cell cycle
arrest and a consequent increase in apoptosis [48]. Simi-
larly, combined treatment of alisertib with platinum-based
drugs appeared particularly beneficial in platinum-resistant
recurrent ovarian cancers and small-cell lung cancers [45,
49]. Interestingly, expression of Aurora-A is positively
associated with resistance to cisplatin-based chemother-
apeutic agents [50]. Possibly, Aurora-A is required to allow
cancer cells to proliferate, despite the presence of DNA
lesions. Such DNA lesions may be introduced through
genotoxic agents and result from DNA repair defects, for
instance caused by BRCA2 inactivation. Of note, Aurora-A
in conjunction with Polo-like kinase-1 was previously
shown to be required to allow cells to restart cell division
in situations of DNA damage [51, 52]. In this context, it is
of interest to determine whether Aurora-A inhibition may
potentiate PARP inhibitor treatment in HR-defective
tumors. PARP inhibition in HR-defective cancer cells
increases the load of DNA lesions [53, 54], which are to a
significant degree transmitted into mitosis [34]. In this
context, Aurora-A inhibition may affect such tumor cells
both at the G2/M-phase transition as well as during mitotic
progression.
862 S. E. van Gijn et al.
Materials and methods
Co-functionality analysis
Using a previously published gene co-regulation network
(available at http://genenetwork.nl), networks of genes that
show a strong predicted co-functionality are constructed.
The likelihood for an individual gene to be part of a bio-
logical pathway (i.e., gene set) is described by a Spearman
correlation coefficient. Based on the co-regulated gene
network, we calculated the correlation coefficients per
individual gene with every gene set as defined in a selected
database (Gene Ontology, KEGG, Reactome, or Biocarta).
This resulted in a vector of n correlation coefficients (i.e.,
functional likelihood vector) for each individual gene. The
number of gene sets in the selected database determines the
number n. Subsequently, the correlation between functional
likelihood vectors of individual genes was calculated (i.e.,
co-functionality correlation). A high co-functionality cor-
relation indicates that two individual genes have similar
predicted biological functions. Genes are plotted in the co-
functionality network when the co-functionality correlation
is above a predefined threshold (correlation coefficient >
0.5).
Cell lines
Human breast cancer cell lines BT-549, MDA-MB-231,
HCC38, and HCC1806 were obtained from ATCC
(#HTB122, #HTB26, #CRL2314, and #CRL2335) and
SUM149 was obtained from Asterand Bioscience. BT-549,
HCC38, and HCC1806 were maintained in RPMI medium
(Invitrogen), supplemented with 10% fetal calf serum
(FCS). Non-transformed human MCF10A breast epithelial
cells (Crl-10317), HeLa human cervical cancer cells
(#CCL2), and HEK293T (#CRL3216) human embryonic
kidney were obtained from ATCC. MDA-MB-231 cells
were cultured in DMEM medium (Invitrogen), supple-
mented with 10% FCS. SUM149 was cultured in Ham/F-12
(1:1) medium (Invitrogen), supplemented with 10% FCS, 1
μg/mL hydrocortisone, and 5 μg/mL insulin (Sigma). DLD-
1 human colorectal adenocarcinoma cells were described
previously [34], and cultured in RPMI with 10% FCS. All
cell lines were cultured in a humidified incubator at 37 °C
and 5% CO2. Mouse mammary tumor cell lines K14-Cre;
Brca2wt/wt;p53F2-10/F2-10, K14-Cre;Brca2F11/F11;p53F2-10/F2-10,
and K14-Cre;Brca2F11/F11;p53F2-10/F2-10+ iBac-Brca2 were
described previously [55–57] and were maintained in
DMEM/F-12 medium (1:1 ratio, Invitrogen), supplemented
with 10% FCS, penicillin (50 U/mL, Invitrogen), strepto-
mycin (50 μg/mL, Invitrogen), insulin (5 μg/mL, Sigma),
epidermal growth factor (5 ng/mL, Preprotech), and cholera
toxin (5 ng/mL, Sigma) at 37 °C under hypoxic conditions
(1% O2 and 5% CO2). Cells were plated 24 h prior to any
treatment or transfection. All cell lines were routinely tested
for mycoplasma infection and authenticated by STR
profiling.
Virus infections
To establish BT-549, MDA-MB-231, SUM149, HCC38,
and HCC1806 cell lines stably expressing doxycycline-
inducible shRNAs, cells were infected with lentiviral par-
ticles as described previously [58]. In short, HEK293T cells
were transfected with 10 μg of pLKO-Tet-Puro-BRCA2 (5′-
AACAACAATTACGAACCAAACTT-3′), in combination
with 4 μg of delta YPR, 2.6 μg of VSV-G, and 1.6 μg of
pAdvantage (Promega). After transfection, supernatant
medium containing virus particles was filtered and trans-
ferred to recipient cells in three subsequent 12-h periods.
Infected cells were selected using puromycin (1 µg/mL,
Sigma). To induce shRNA expression, shBRCA2-recipient
cells were treated with doxycycline (1 µg/mL) for 48 or
72 h.
To generate cell lines overexpressing TPX2, human TPX2
was amplified using pmCherry-TPX2 as a template, which
was a kind gift from Patricia Wadsworth (Addgene plasmid
#31227) [59]. The TPX2 transcript was PCR amplified using
the following primers: forward: (5′-GATCCATGAAAGTTT
CTAACAACAAA-3′) and reverse (5′-AATTCAAAAAAT
GAAAGTTTCTAACAACAAA-3′). The resulting PCR
product was cloned into pBabe-hygro using the BamHI and
EcoRI restriction sites. The pBabe-hygro plasmid was a kind
gift from Hartmut Land and Jay Morgenstern and Bob
Weinberg (Addgene plasmid #1765). The resulting plasmid
was verified using Sanger sequencing using the following
primer: (5′-GAAATTTGTGATGCTATTGC-3′). Subse-
quently, BT-549-shBRCA2dox [60] cells were retrovirally
infected with pBabe-TPX2 or pBabe-EV (empty vector). To
this end, HEK293T cells were transfected with 10 μg of
pBabe-EV or with pBabe-TPX2 combined with 2.5 μg of
pMD/p and 7.5 μg of pMDg packaging plasmids as described
previously [61]. The supernatant was collected, filtered, and
transferred to BT-549-shBRCA2dox cells in three subsequent
12-h periods. Recipient cells were selected with hygromycin
(200 μg/mL, Sigma).
RNA interference
Two independent Stealth siRNA targeting sequences
(ThermoFisher Scientific) were used for the following
genes: BIRC5, UBE2C, CENPA, TPX2, KIF2C, DEK,
CDCA3, SKP2, RAD21, MYBL2, andWDR67 (Table 1). For
each transfection, Stealth siRNA negative control (ctrl)
scrambled sequences were taken along. Cells were trans-
fected with siRNAs (final concentration of 133 nM) in Opti-
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MEM (Life Technologies) at 80–90% confluency using
Oligofectamine (Invitrogen). Forty-eight hours after trans-
fection, cells were trypsinized and counted using a counting
chamber and were replated at 30,000 cells per well in a six-
well plate in the presence or absence of doxycycline (1 µg/
mL). After 5 days, cells were trypsinized and the amounts
of living cells per well were counted.
Immunofluorescence microscopy
Doxycycline-inducible cell lines were grown on coverslips
and treated with doxycycline (1 µg/mL) for 3 days or cells
were left untreated. If indicated, cells were irradiated (5 Gy)
using a CIS international/IBL 637 cesium137 source (dose
rate: 0.010124 Gy/s). After 3 h of irradiation, cells were
fixed with 2% paraformaldehyde, permeabilized in 0.1%
Triton X-100 in PBS, blocked in 4% bovine serum albumin
(BSA) in PBS, and incubated with primary antibodies
against RAD51 (GeneTex, #gtx70230, 1:400) and γH2AX
(Cell Signaling, #9718, 1:200). Secondary antibodies
Alexa-488 or Alexa-647 (1:500) were used and slides were
stained with DAPI. Images were made using a Leica
DM6000B microscope with a ×63 immersion objective.
Western blotting
Cells were lysed in ice-cold M-Per lysis buffer (Pierce),
complemented with 1% protease and 1% phosphatase
inhibitor cocktail (Roche). Proteins were then separated on
SDS-polyacrylamide gels (SDS-PAGE) and electro-
phoretically transferred onto a PVDF membrane (Milli-
pore). Membranes were blocked with 5% skimmed milk
(Sigma) in Tris-buffered saline (TBS) with 0.05% Tween-
20 (Sigma) and probed with specific antibodies recognizing
BRCA2 (Millipore, OP95, 1:1000), TPX2 (Novus Biolo-
gicals, NB500-179, 1:1000), Aurora-A (Abcam, ab13824,
1:1000), Aurora-A (phospho-Thr288)/Aurora-B (phospho-
Thr232)/Aurora-C (phospho-Thr198) (Cell Signal-
ing#2914), or β-actin (MP Biomedicals, #69100, 1:2000).
Horseradish peroxidase-conjugated secondary antibodies
(DAKO) were diluted 1:2000 and were visualized using
chemiluminescence (Lumi-Light, Roche Diagnostics) on a
Bio-Rad bioluminescence device. Images were made using
Quantity One/ChemiDoc XRS software (Bio-Rad).
Flow cytometry
Cells were fixed in ice-cold 70% ethanol, and incubated
overnight at 4 °C. Subsequently, cells were stained for
rabbit anti-phospho-histone H3 antibody (1:100, Cell Sig-
nalling, #9701) and mouse MPM2 (1:100, Millipore, 05-
368). After washing with PBS–0.05% Tween-20, cells were
incubated with Alexa 488-conjugated and Alexa 647-
conjugated secondary antibodies (1:100, Molecular
Probes) and counterstained with propidium iodide/RNase
(Sigma). FACS analyses were performed on a FACS-
Calibur (Becton Dickinson) and samples were analyzed
using Cell Quest software. Data were analyzed using
FlowJo software. At least 10,000 events were analyzed per
sample.
cDNA synthesis and qRT-PCR
RNA was isolated from frozen cell pellets using the RNeasy
kit (Qiagen). Between 100 ng and 1 μg of total RNA was
reverse transcribed into cDNA using Superscript III (Bio-
Rad). The resulting first-strand cDNA was used as a tem-
plate in the qRT-PCR. Samples were amplified using the
Table 1 siRNA sequences
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indicated primers (Table 2), cDNA, and a SYBR Green
master mix (Bio-Rad).
Clonogenic and short-term survival assays
For clonogenic survival assays, cells were cultured in six-
well plates. When colonies reached a size of approximately
50 cells, typically after 10–14 days, colonies were washed
with PBS, fixed with methanol, and subsequently stained
with Coomassie Brilliant Blue (CBB). Amounts of surviv-
ing colonies in drug-treated samples were normalized to
DMSO-treated samples. For short-term survival assays,
cells were treated with alisertib with indicated concentra-
tions for 4 days after which methyl-thiazol-tetrazolium
(MTT) (5 mg/mL) was added. After 4 h, the medium was
removed and DMSO was added to dissolve formazan
crystals. Absorbance values were measured on a Bio-Rad
benchmark III Biorad spectrophotometer and they were
normalized to DMSO absorbance values.
Live-cell microscopy
BT-549 cells were transduced with H2B-EGFP as pre-
viously described [34], and plated in eight-chambered cover
glass plates (Lab-Tek-II, Nunc). Doxycycline-inducible
cells were treated with doxycycline for 24 h to induce
BRCA2 depletion prior to live-cell microscopy. Cells were
followed using a DeltaVision Elite microscope with a ×20
objective. Cells were tracked for 60–65 h or until they
migrated out of frame. Every 6 min, six images were taken
in the z-axis with an interval of 0.5 μm. Time-lapse images
were made and analyzed using SoftWorX software (Applied
Precision/GE Healthcare). Duration of mitosis was quanti-
fied from prometaphase to anaphase. Aberrant mitoses
included unequal chromosome segregation, absence of a
bipolar spindle, or cytokinesis failure.
Single-cell whole-genome analysis
BT-549-shBRCA2#2dox cells were treated with doxycycline
(1 μg/mL) or alisertib (200 nM) as indicated, and after 72 h,
cells were single-cell sorted into 96-well plates (48 cells per
condition), using a Hoechst/propidium iodide double
staining. Only G1 cells were included. Cells were then
lysed, and DNA was sheared. DNA was barcode-labeled,
followed by library preparation as described previously
[62], in an automated fashion using an Agilent Bravo robot.
Single-cell libraries were pooled and analyzed on an Illu-
mina Hiseq2500 sequencer. Sequencing data was analyzed
using AneuFinder software as described previously [63].
Focal deviations and whole-chromosome deviations from
the modal state in control-treated BT-549 samples were
analyzed.
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Table 2 qRT-PCR primers
Genes Forward primer 5′–3′ Reverse primer 5′–3′
BIRC5 TCAAGGACCACCGCATCTCTA TGAAGCAGAAGAAACACTGGGC
UBE2C TGATGTCTGGCGATAAAGGGATT GTGATAGCAGGGCGTGAGGAA
CENPA CTTCCTCCCATCAACACAGTC TGCTTCTGCTGCCTCTTGTAG G
TPX2 CGAAAGCATCCTTCATCTCC TCCTTGGGACAGGTTGAAAG
KIF2C ACTCTAGGACTTGCATGATTGCC TGGGTGT CAAACCAAACAGA
DEK TGTTAAGAAAGCAGATAGCAGCACC ATTAAAGGTTCATCATCTGAACTATCCTC
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long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
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